IN8BIO, INC.
About IN8BIO, INC.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$19.4M
- Total assets
- $32.3M
- Market cap
- $13.9M
- Operating margin
- -4617.6%
- Net margin
- -4617.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $421.0K
- Operating expenses
- $19.9M
- Operating income
- -$19.4M
- Income tax
- -$2.4M
- Net income
- -$19.4M
- EPS (basic)
- $-4.44
- EPS (diluted)
- $-4.44
Balance sheet
- Total assets
- $32.3M
- Current assets
- $27.9M
- Total liabilities
- $4.7M
- Current liabilities
- $3.2M
- Shareholders’ equity
- $27.6M
Cash flow
- Operating cash flow
- -$12.7M
- Investing cash flow
- -$15.9M
- Financing cash flow
- $28.6M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.9M
- EPS (diluted)
- $-4.44
- Shares outstanding
- 9.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 30, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $19.4M.
- Trading 71% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review IN8BIO, INC..
Write a review
News about IN8BIO, INC.
News & sentiment via Polygon.io
